Mechanisms Underlying Olfactory Dysfunction in Aging and Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias
ID: 360893Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) aimed at investigating the mechanisms underlying olfactory dysfunction in aging, Alzheimer’s disease (AD), and Alzheimer’s disease-related dementias (ADRD). This initiative seeks to explore the relationship between olfactory decline and various health outcomes in older adults, potentially identifying novel therapeutic targets for disease modification. The research may involve studies on older adults and animal models, utilizing diverse methodologies such as cellular, molecular, and imaging techniques. While applications are not currently being solicited, interested researchers are encouraged to prepare collaborative projects in anticipation of the funding opportunity, which is expected to utilize the R01 activity code. For further inquiries, contact Coryse St. Hillaire-Clarke, Ph.D., at 301-496-9350 or via email at sthillaireclacn@mail.nih.gov. The estimated synopsis post date is August 6, 2026, with a closing date for applications anticipated on October 6, 2026, and awards expected to be made by July 6, 2027.

    Point(s) of Contact
    Coryse St. Hillaire-Clarke, Ph.D.
    (301) 496-9350
    sthillaireclacn@mail.nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Transformative Non-Invasive/Minimally Invasive Technologies for Imaging the Olfactory System Across Scales (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "Transformative Non-Invasive/Minimally Invasive Technologies for Imaging the Olfactory System Across Scales (R01 Clinical Trial Optional)." This initiative aims to solicit research applications focused on developing advanced non-invasive and minimally invasive imaging technologies to visualize the human olfactory system, addressing the current limitations in imaging techniques that hinder understanding of olfactory disorders. The opportunity emphasizes the need for multimodal approaches and encourages collaborations among experts in various fields such as olfaction, biomedical imaging, and bioengineering. Interested applicants should note that applications are not currently being solicited, but they can prepare for submission as the estimated synopsis post date is October 27, 2025, with a closing date of November 27, 2025. For further inquiries, potential applicants can contact Dr. Merav Sabri at merav.sabri@nih.gov or by phone at 301-827-5992.
    Understanding Cerebellar Contributions to Cognitive and Affective Functions in Aging and Alzheimer's Disease/Alzheimer's Disease-Related Dementias
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming Notice of Funding Opportunity (NOFO) aimed at advancing research on the cerebellum's role in cognitive and affective functions related to aging and Alzheimer's disease (AD) as well as Alzheimer's disease-related dementias (ADRD). This initiative seeks to enhance understanding of the cerebellum's physiology and neuroanatomy, encouraging a variety of research approaches, including basic studies, secondary data analyses, and intervention-focused research. The NOFO is particularly significant as it aims to identify potential targets for interventions that could promote cognitive reserve and delay the onset of AD/ADRD. Interested researchers are encouraged to prepare collaborative proposals, with applications expected to be solicited in the future; for inquiries, contact Matt Sutterer, Ph.D., at matt.sutterer@nih.gov. The estimated synopsis post date is August 6, 2026, with a projected award date of July 6, 2027.
    Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at supporting early- and late-stage clinical trials focused on Alzheimer's Disease (AD), Alzheimer's Disease-Related Dementias (ADRD), and age-related cognitive decline. This initiative seeks applications that propose innovative pharmacological and non-pharmacological interventions to address cognitive, behavioral, and neuropsychiatric changes associated with these conditions, as well as studies to enhance trial design and methodologies. The funding opportunity, categorized under health-related discretionary grants, is intended for small businesses with expertise in aging research, with an estimated synopsis posting date of August 1, 2025, and a closing date for applications expected by October 5, 2025. For further inquiries, interested applicants can contact Laurie Ryan, Ph.D., at 301-496-9350 or via email at ryanl@mail.nih.gov.
    Novel Approaches to Advance Precision Aging and Cognitive Health
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) titled "Novel Approaches to Advance Precision Aging and Cognitive Health," aimed at soliciting applications that leverage innovative study designs and methods, including machine learning and artificial intelligence, to enhance cognitive health in older adults. This initiative seeks to develop personalized prevention plans and interventions by discovering health and function profiles at the individual level, encompassing research from cellular to societal levels. The grant will utilize the R01 activity code, with applications not currently being solicited; however, potential applicants are encouraged to begin forming collaborations and project ideas in anticipation of the funding opportunity. For further inquiries, interested parties may contact Dr. Molly Wagster at wagsterm@nia.nih.gov or by phone at 301-496-9350. The estimated synopsis post date is August 6, 2026, with a close date of October 6, 2026, and an anticipated award date of July 6, 2027.
    Notice of Intent to Publish a Notice of Funding Opportunity for Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for early- and late-stage clinical trials focused on Alzheimer's Disease, Alzheimer's Disease-Related Dementias, and age-related cognitive decline. This initiative aims to invite applications that propose innovative pharmacological and non-pharmacological interventions to address cognitive and behavioral changes associated with these conditions, as well as to enhance trial design and methodologies. The NOFO is expected to be published in December 2024, with application due dates in March, June, and October of 2025, and an estimated award date set for December 1, 2025. Interested applicants are encouraged to prepare collaborative projects in advance, as there are no cost-sharing requirements associated with this grant opportunity.
    Discovery of in vivo Chemical Probes for the Nervous System
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at supporting the discovery of in vivo chemical probes for the nervous system, specifically targeting novel brain mechanisms. This initiative, led by the National Institute on Aging (NIA) in collaboration with the National Eye Institute (NEI), the National Institute on Drug Abuse (NIDA), and the National Institute of Mental Health (NIMH), seeks applicants who possess validated starting compounds for chemical optimization and bioassays to explore new analog compounds. The focus will be on developing small molecules that can enhance understanding of biological processes relevant to brain diseases, with an emphasis on innovative biological targets. Interested applicants can reach out to Dr. Paul G. Grothaus at grothausp@mail.nih.gov or call 240-688-6634 for further information, with the estimated synopsis posting date set for February 26, 2026, and a projected award date of April 5, 2027.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD) through the R01 grant mechanism. This initiative aims to encourage studies that enhance understanding of the biobehavioral and neurobiological mechanisms associated with NPS, with the goal of identifying novel therapeutic targets for treatment and prevention. The research is critical for improving care and management strategies for patients and caregivers affected by these conditions, aligning with national efforts to combat Alzheimer's disease. Applications are accepted from a diverse range of eligible institutions, with key submission dates from January 5, 2025, to June 5, 2026. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-065.html.
    AD/ADRD Clinical Trials Short Course
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the AD/ADRD Clinical Trials Short Course aimed at enhancing the workforce skilled in Alzheimer's disease (AD) and AD-related dementias (ADRD) clinical trials. This initiative seeks to develop innovative short courses that will train the next generation of clinical trialists in advanced research skills pertinent to AD, frontotemporal dementia (FTD), Lewy body dementia (LBD), vascular contributions to cognitive impairment and dementia (VCID), and mixed dementia, as well as interventions for treatment and prevention. While applications are not currently being solicited, potential applicants are encouraged to begin forming collaborations and project ideas in anticipation of the funding opportunity, which will utilize the R25 activity code. For further inquiries, interested parties can contact Laurie Ryan at the National Institute on Aging via email at ryanl@mail.nih.gov or by phone at 301-496-9350. The estimated synopsis post date is September 1, 2025, with a closing date for applications expected by January 25, 2026, and an anticipated award date of December 1, 2026.
    Dementia Care and Caregiver Support Intervention Research - Stages II - V
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to release a Notice of Funding Opportunity (NOFO) for research applications focused on developing behavioral interventions for individuals living with Alzheimer's disease and related dementias, as well as their caregivers. This initiative aims to support a milestone-driven planning phase lasting up to two years, with the potential for transition to a clinical trial phase upon successful completion of the required milestones. The funding opportunity is particularly significant as it addresses critical health challenges associated with aging and dementia care. Interested small businesses are encouraged to prepare for this opportunity, with the estimated synopsis posting date set for November 1, 2025, and applications expected to close by February 16, 2026. For further inquiries, potential applicants can contact Dr. Melissa Riddle at melissa-riddle@nih.gov or by phone at 301-480-6761.
    Biomarkers of Cognitive Decline and Dementias of Aging in Individuals within the Autism Spectrum
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to release a Notice of Funding Opportunity (NOFO) aimed at supporting observational studies focused on biomarkers of cognitive decline and dementias of aging in individuals on the Autism Spectrum. The primary objective of this initiative is to investigate age-related neurodegeneration within the Autism Spectrum Disorders (ASD) population, characterize the physiopathology of Alzheimer's disease and related dementias, and develop precision-medicine strategies tailored to this unique group. This funding opportunity encourages collaborations between researchers specializing in autism and those with expertise in aging and dementia, fostering interdisciplinary approaches to address this critical area of health research. Interested applicants can reach out to Dr. Alessandra Rovescalli at rovescaa@mail.nih.gov or by phone at 301-215-0335 for further information, with the estimated synopsis posting date set for December 1, 2025, and applications expected to be solicited by February 5, 2026.